Ketotifen

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X49220T18G, chemically known as 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one but generally known as ketotifen, which bears US NIH Compound Identifier 3827. European Medicines Agency schedules Ketotifen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08377MIG. The term KETOTIFEN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules ketotifen in its Anatomical Therapeutic Chemical (ATC) Classification. KETOTIFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ketotifen under HS 29349990 and SITC 51579. As of Q4 2014, KETOTIFEN remains the US FDA Preferred Term for this commodity. Ketotifen bears US NLM identifiers UMLS ID C0022642 and NCI Concept Code C61799. SMILES: S1C2C(C(=C3\CCN(CC3)C)/C3C(CC2=O)CCCC3)CC1.